Searching for Biological Markers in People With Neurodegenerative Diseases Such as Alzheimer's and Parkinson's
Studies genes, proteins and other body markers in adults with neurodegenerative diseases.
Plain-language title generated from the registry record
Registry title: Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
Key facts
- Where
- Genoa, ItalySee the site
Where in Italy
- Ospedale Policlinico San MartinoGenoa, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ospedale Policlinico San Martino
- Trial code
- NCT07235111
- Record updated
- 25 November 2025
- Original description
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and to obtain a new and more complete characterisation of subjects affected by the neurodegenerative diseases under study. Thanks to the integration of genomic, gene expression (transcriptomic and epigenomic), protein and metabolic data and clinical data, the study also aims to identify new markers for the diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases.Read full original descriptionShow less
Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and to obtain a new and more complete characterisation of subjects affected by the neurodegenerative diseases under study. Thanks to the integration of genomic, gene expression (transcriptomic and epigenomic), protein and metabolic data and clinical data, the study also aims to identify new markers for the diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases.
The study involves the enrolment of at least 1.200 individuals with neurodegenerative disease.
Inclusion: Patients suffering from neurodegenerative diseases.
Exclusion: Patients not suffering from neurodegenerative diseases.